Amgen, the American company, has received a registration certificate from the Ministry of Health of the Russian Federation for its groundbreaking antitumor drug, Lumicras (Sotorasib). The active ingredient sotorasib, a KRAS mutation inhibitor, fights locally advanced or metastatic non-small cell lung cancer that contains it.
Lumicras is obtainable in tablet form, with a strength of 120 mg. The patient should take eight tablets (960 mg) per day. The drug should not be administered to individuals under the age of 18 or to pregnant and breastfeeding women, as it may have adverse effects. The drug was approved in the USA in 2021 on an accelerated basis.
